Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19.

ABSTRACT:

Introduction

Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients.

Methods

We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed.

Results

Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (

SUBMITTER: Buxeda A 

PROVIDER: S-EPMC8257403 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature